Recent Updates
Recently added Catalysts
TMDX Positive Sentiment

TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. has announced it will release its financial results for the first quarter of 2023 after market close on May 1, 2023. A conference call will follow, allowing investors to engage directly with the management team. The company is recognized as a leader in portable warm perfusion for organ transplants, focusing on improving organ quality and viability. This announcement highlights TransMedics' ongoing efforts in the organ transplant sector.
Price reaction · baseline $66.23 (2023-04-14 close) · clean, no other TMDX news in the window
day 0 close
+5.1%
day 1
+7.5%
day 3 · peak
+19.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is set to release its first quarter financial results, indicating active business operation.
  • The company is a leader in innovative organ transplant technologies, suggesting strong market position.
  • The scheduled conference call reflects transparency with investors.

Full Press Release Details

ANDOVER, Mass. , April 17, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Frequently Asked Questions

When will TransMedics release Q1 2023 financial results?

TransMedics will release its Q1 2023 financial results on May 1, 2023.

What time is the TransMedics conference call?

The conference call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT.

How can investors access the conference call?

Investors can call (866) 807-9684 for domestic or (412) 317-5415 for international access.

Where can I find more information about TransMedics?

More information is available on the Investors section of the TransMedics website.

What does TransMedics specialize in?

TransMedics specializes in organ transplant technologies for heart, lung, and liver failure.

Last updated: Apr 17, 2023